AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32641081 — intervention group
Group type: COMPARATOR
Intervention: Normal diet alone (control arm)
Number of subjects: 176
Study 32641081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition
Number of subjects: 176
Study 34942330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/Mineral Supplement (MVM)
Number of subjects: 0
Study 34942330 — intervention group
Group type: EXPERIMENTAL
Intervention: MVM plus Choline
Number of subjects: 0
Study 34942330 — intervention group
Group type: COMPARATOR
Intervention: No study‐provided supplements
Number of subjects: 0
Study 34942330 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal levels of DMG
Number of subjects: 0
Study 34942330 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal levels of betaine in Trimester 3
Number of subjects: 0
Study 33478494 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum levonorgestrel IUD placement
Number of subjects: 32
Study 33478494 — intervention group
Group type: COMPARATOR
Intervention: Delayed postpartum levonorgestrel IUD placement
Number of subjects: 32
Study 34674779 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mobile meditation sessions
Number of subjects: 30
Study 34674779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 35066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting persistent positive margins after margin re-excision
Number of subjects: 289
Study 35066720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and pathologic variables used in the nomogram
Number of subjects: 289
Study 32964140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive app linked to primary care EHRs
Number of subjects: 934
Study 32964140 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (Control)
Number of subjects: 934
Study 32536286 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel femoral artery compression device (NFACD)
Number of subjects: 617
Study 32536286 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 617
Study 32769533 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 25
Study 32769533 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality and Technique Guide (VR + TG)
Number of subjects: 25
Study 32769533 — intervention group
Group type: COMPARATOR
Intervention: Technique Guide (TG)
Number of subjects: 25
Study 36493842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored best practice advisory embedded within the electronic health record
Number of subjects: 1012
Study 36493842 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 1012
Study 34229859 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.02 mg.kg‐1.h‐1)
Number of subjects: 100
Study 34229859 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.3 mcg.kg‐1.h‐1)
Number of subjects: 100
Study 34229859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Morphine and Fentanyl
Number of subjects: 100
Study 32343918 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine infusion (SCLI) at a dosage of 10 mg/kg over 5.5 hours
Number of subjects: 2
Study 32343918 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 2
Study 33447371 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolbachia mosquitoes releases
Number of subjects: 1100000
Study 33447371 — intervention group
Group type: COMPARATOR
Intervention: Control areas (untreated)
Number of subjects: 1100000
Study 35210767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics prescribed in the prior 12 months
Number of subjects: 649
Study 35210767 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (compared to normal body mass index)
Number of subjects: 649
Study 35210767 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 649
Study 33558350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 336
Study 33558350 — intervention group
Group type: COMPARATOR
Intervention: References intakes (RIs)
Number of subjects: 336
Study 33558350 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 336
Study 32795381 — intervention group
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention (individualized plan of care from an interprofessional care team)
Number of subjects: 0
Study 32795381 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 33867880 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients presenting with symptoms of <1 week
Number of subjects: 500
Study 33867880 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from outside ophthalmologist
Number of subjects: 500
Study 33867880 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals from outside hospital
Number of subjects: 500
Study 33867880 — intervention group
Group type: COMPARATOR
Intervention: Nonemergent visits
Number of subjects: 500
Study 32431283 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Health Wizard Hepatitis B Best Practice Alert (BPA)
Number of subjects: 4500
Study 35889796 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3−-rich concentrated beetroot juice (NIT; 12.8 mmol)
Number of subjects: 12
Study 35889796 — intervention group
Group type: COMPARATOR
Intervention: NO3−-depleted concentrated beetroot juice (PLA; 0.04 mmol)
Number of subjects: 12
Study 33399136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hairstylists with CTS symptoms (73 out of 165, 42.2% prevalence); majority (73%) being females.
Number of subjects: 165
Study 33399136 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual factors associated with CTS symptoms: being female (OR 9.99, 95% CI: 3.64-27.44), increasing age (OR 9.84, 95% CI: 2.74-35.36), length of employment (OR 3.73, 95% CI: 1.39-9.95), hair washing (OR 2.88, 95% CI: 1.41-5.85), awkward posture (OR 2.52, 95% CI: 1.03-6.19), great muscular effort (OR 2.39, 95% CI: 1.01-5.72).
Number of subjects: 165
Study 35871473 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 4% sucralfate cream four times a day for 2 months
Number of subjects: 44
Study 35871473 — intervention group
Group type: COMPARATOR
Intervention: Peristomal wound care alone (Control)
Number of subjects: 44
Study 34508901 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg)
Number of subjects: 54
Study 34508901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 34882608 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combination of omega‐3 and omega‐6 fatty acids (1200 mg eicosapentaenoic acid, 300 mg docosahexaenoic acid, 150 mg γ‐linoleic acid)
Number of subjects: 50
Study 34882608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (coconut and olive oil)
Number of subjects: 50
Study 34882608 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combination of omega‐3 and omega‐6 fatty acids
Number of subjects: 50
Study 34882608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32188326 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 304
Study 32188326 — intervention group
Group type: COMPARATOR
Intervention: 7+3
Number of subjects: 304
Study 35041248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (CDRI 08®)
Number of subjects: 93
Study 35041248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 32779011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ)
Number of subjects: 56
Study 32779011 — intervention group
Group type: COMPARATOR
Intervention: GC dry mouth gel (GC)
Number of subjects: 56
Study 33666009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated screw internal fixation
Number of subjects: 1068
Study 33666009 — intervention group
Group type: COMPARATOR
Intervention: Bone plate internal fixation
Number of subjects: 1068
Study 32969104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) program, 8 sessions of 1.5 hours each
Number of subjects: 41
Study 36459398 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-led, one-on-one, home-based digital literacy program
Number of subjects: 138
Study 36459398 — intervention group
Group type: COMPARATOR
Intervention: Control group (older adults awaiting participation in the program)
Number of subjects: 138
Study 33865472 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free-home intervention plus indoor-air-quality feedback
Number of subjects: 1801
Study 33865472 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free-home intervention only
Number of subjects: 1801
Study 33865472 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 1801
Study 33561016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Alhydrogel
Number of subjects: 10
Study 33561016 — intervention group
Group type: COMPARATOR
Intervention: Pfs25-EPA
Number of subjects: 10
Study 32444040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aq+ (3056 mg day-1)
Number of subjects: 30
Study 32444040 — intervention group
Group type: COMPARATOR
Intervention: Glu (2000 mg day-1)
Number of subjects: 30
Study 35039174 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROVE programme (multifaceted implementation including educational activities, audit and feedback, reminders, organisational, team-directed, and patient-mediated activities)
Number of subjects: 1934
Study 35039174 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROVE programme
Number of subjects: 1934
Study 34868084 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (weekly 700 mg)
Number of subjects: 0
Study 34868084 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (weekly treatment)
Number of subjects: 0
Study 32901330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib (5 mg once daily for 3 weeks, followed by 1 week off in 28-day cycles)
Number of subjects: 363
Study 32901330 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 363
Study 35343430 — intervention group
Group type: EXPERIMENTAL
Intervention: New sodium valproate formulation (epilenil 500‐mg coated tablet)
Number of subjects: 0
Study 35343430 — intervention group
Group type: COMPARATOR
Intervention: Depakene formulation
Number of subjects: 0
Study 34737416 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Sampling
Number of subjects: 0
Study 34737416 — intervention group
Group type: COMPARATOR
Intervention: Admission Blood Sampling
Number of subjects: 0
Study 33172957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese patients who lost weight (≥5%)
Number of subjects: 1869
Study 33172957 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight or normal weight women who lost weight (≥5%)
Number of subjects: 1869
Study 33172957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese patients
Number of subjects: 1869
Study 33172957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of 1869 women
Number of subjects: 1869
Study 34384419 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Arthrodesis (PA)
Number of subjects: 112
Study 34384419 — intervention group
Group type: COMPARATOR
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 112
Study 33118638 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive‐Affective Therapy for BED
Number of subjects: 112
Study 33118638 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy delivered using guided self‐help
Number of subjects: 112
Study 34427006 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-Anon Intensive Referral (AIR)
Number of subjects: 279
Study 34427006 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 279
Study 34180157 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 34180157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36159262 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab plus chemotherapy
Number of subjects: 2
Study 33619171 — intervention group
Group type: EXPERIMENTAL
Intervention: m276-SL-PBD (0.5 mg/kg on days 1, 8, and 15)
Number of subjects: 26
Study 33619171 — intervention group
Group type: EXPERIMENTAL
Intervention: m276-SL-PBD (single 0.5 mg/kg dose)
Number of subjects: 26
Study 33619171 — intervention group
Group type: COMPARATOR
Intervention: m276-SL-PBD
Number of subjects: 26
Study 32203234 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-led approach (BLISS)
Number of subjects: 206
Study 32203234 — intervention group
Group type: COMPARATOR
Intervention: Traditional spoon-feeding (Control)
Number of subjects: 206
Study 33637429 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate cognitive processing intervention (developing contingency plans)
Number of subjects: 78
Study 33637429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific instructions)
Number of subjects: 78
Study 33637429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 33238982 — intervention group
Group type: EXPERIMENTAL
Intervention: LIM nomogram developed from logistic regression analysis
Number of subjects: 3797
Study 33238982 — intervention group
Group type: EXPERIMENTAL
Intervention: LIM nomogram
Number of subjects: 3797
Study 35863366 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg)
Number of subjects: 3780
Study 35863366 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin monotherapy (rosuvastatin 20 mg)
Number of subjects: 3780
Study 35863366 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 3780
Study 35863366 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin monotherapy
Number of subjects: 3780
Study 34705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with a laser wavelength of 660 nm
Number of subjects: 60
Study 34705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with a laser wavelength of 808 nm
Number of subjects: 60
Study 34705999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no light treatment)
Number of subjects: 60
Study 34705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (equipment switched off)
Number of subjects: 60
Study 32388895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy
Number of subjects: 93
Study 32388895 — intervention group
Group type: COMPARATOR
Intervention: Control (no metastasectomy)
Number of subjects: 93
Study 32388895 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary metastasectomy vs Control
Number of subjects: 93
Study 35780241 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly educational one-way text messages on sexo-reproductive health
Number of subjects: 398
Study 32658515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral prevention (CBP) program
Number of subjects: 298
Study 32658515 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 298
Study 34635005 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT tool (ARATA)
Number of subjects: 78
Study 34635005 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 78
Study 34301734 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated unlimited access to outpatient visits
Number of subjects: 357
Study 34301734 — intervention group
Group type: COMPARATOR
Intervention: Usual care through regular prescheduled visits
Number of subjects: 357
Study 32427354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of voriconazole (VRZ) at 7.5 mg/h from 8 to 16 hours and 15 mg/h from 16 to 24 hours combined with midazolam (MDZ) at 0.26 mg/h for 24 hours
Number of subjects: 6
Study 32427354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of voriconazole (VRZ) at 7.5 mg/h from 8 to 16 hours and 15 mg/h from 16 to 24 hours combined with midazolam (MDZ) at 0.26 mg/h for 24 hours
Number of subjects: 6
Study 36454199 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 44
Study 36454199 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no VR)
Number of subjects: 44
Study 33308274 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin application (depth and dose not specified)
Number of subjects: 0
Study 33308274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control treatment groups)
Number of subjects: 0
Study 35938323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Xingshen acupuncture and moxibustion combined with cognitive training
Number of subjects: 84
Study 35938323 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (control group)
Number of subjects: 84
Study 32719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-stable cross-linked collagen matrix (VCMX)
Number of subjects: 12
Study 32719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cross-linked collagen matrix (XCM)
Number of subjects: 12
Study 32719982 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 12
Study 34775069 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI+6L group
Number of subjects: 390
Study 34775069 — intervention group
Group type: COMPARATOR
Intervention: PVI group
Number of subjects: 390
Study 34853062 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan
Number of subjects: 3668
Study 34853062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3668
Study 32183911 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 551
Study 32183911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged 20-39 years
Number of subjects: 551
Study 32183911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged 40-59 years
Number of subjects: 551
Study 32183911 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who had lost their jobs
Number of subjects: 551
Study 35503345 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure self-monitoring with telemonitoring
Number of subjects: 850
Study 35503345 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study 35503345 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring group
Number of subjects: 850
Study 33516143 — intervention group
Group type: EXPERIMENTAL
Intervention: KXS 3.2 g/day
Number of subjects: 134
Study 33516143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 36362743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical extension traction (SG)
Number of subjects: 30
Study 36362743 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stretching and exercises + infrared radiation (SG)
Number of subjects: 30
Study 36362743 — intervention group
Group type: COMPARATOR
Intervention: Neck stretching and exercises + infrared radiation (CG)
Number of subjects: 30
Study 36362743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatomal somatosensory evoked potentials (DSSEPS) (both groups)
Number of subjects: 30
Study 36362743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lordosis (CL) correlation (both groups)
Number of subjects: 30
Study 36362743 — intervention group
Group type: EXPERIMENTAL
Intervention: DSSEPs correlation (SG)
Number of subjects: 30
Study 32967646 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-Centered Representative Payee (CCRP)
Number of subjects: 160
Study 32967646 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 160
Study 32967646 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRP
Number of subjects: 160
Study 35910937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness yoga for 4 weeks
Number of subjects: 0
Study 35910937 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no mindfulness yoga)
Number of subjects: 0
Study 35092962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion (FETO)
Number of subjects: 41
Study 35092962 — intervention group
Group type: COMPARATOR
Intervention: Control (antenatal expectant management)
Number of subjects: 41
Study 32882101 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 50
Study 37946220 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics plus atomoxetine
Number of subjects: 80
Study 37946220 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine only
Number of subjects: 80
Study 32479187 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 234
Study 35179044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 52
Study 35179044 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 52
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐directed learning
Number of subjects: 0
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory learning
Number of subjects: 0
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed‐Circuit Television (CCTV)
Number of subjects: 0
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTV‐plus (with feedback)
Number of subjects: 0
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (all phases combined)
Number of subjects: 0
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: After-WHO moments
Number of subjects: 0
Study 34321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Before-WHO moments
Number of subjects: 0
Study 33352920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (3200 IU D3/day)
Number of subjects: 30
Study 33352920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 30
Study 35022282 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily plus FOLFIRI regimen (5-fluorouracil, leucovorin, irinotecan)
Number of subjects: 54
Study 35022282 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI regimen (5-fluorouracil, leucovorin, irinotecan)
Number of subjects: 54
Study 35022282 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus FOLFIRI regimen
Number of subjects: 54